An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
出版年份 2019 全文链接
标题
An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
作者
关键词
-
出版物
EXPERT OPINION ON PHARMACOTHERAPY
Volume 21, Issue 3, Pages 275-285
出版商
Informa UK Limited
发表日期
2019-12-03
DOI
10.1080/14656566.2019.1695779
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
- (2019) Maria J. Pereira et al. DRUGS
- Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non‐surgical and bariatric surgery patients
- (2019) Mohamed Suliman et al. DIABETES OBESITY & METABOLISM
- Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood
- (2019) Amit V. Khera et al. CELL
- Liraglutide in Children and Adolescents with Type 2 Diabetes
- (2019) William V. Tamborlane et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Protocol to Deliver Intensive Behavioral Therapy (IBT) for Obesity in Primary Care Settings: The MODEL‐IBT Program
- (2019) Thomas A. Wadden et al. Obesity
- Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity
- (2018) Christina C. Nexøe-Larsen et al. DIABETES OBESITY & METABOLISM
- Obesity Pharmacotherapy
- (2018) Katherine H. Saunders et al. MEDICAL CLINICS OF NORTH AMERICA
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- The epidemiology of obesity
- (2018) Yu Chung Chooi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
- (2018) Erin A. Bohula et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetics and epigenetics in obesity
- (2018) Kerstin Rohde et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Pharmacotherapy of obesity: Available medications and drugs under investigation
- (2018) Eleni Pilitsi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- (2017) Carel W le Roux et al. LANCET
- Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
- (2017) Philip R. Schauer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms, Pathophysiology, and Management of Obesity
- (2017) Steven B. Heymsfield et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis
- (2017) Carel le Roux et al. Obesity Facts
- Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects
- (2016) Harold Bays et al. CURRENT MEDICAL RESEARCH AND OPINION
- Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
- (2016) Michael Nauck et al. DIABETES CARE
- Response to Comment on Crews et al. Role and Determinants of Adherence to Off-loading in Diabetic Foot Ulcer Healing: A Prospective Investigation. Diabetes Care 2016;39:1371–1377
- (2016) Ryan T. Crews et al. DIABETES CARE
- Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials
- (2016) J. Ard et al. DIABETES OBESITY & METABOLISM
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial
- (2016) Anders Jorsal et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes
- (2016) Brian Tomlinson et al. Expert Opinion on Drug Metabolism & Toxicology
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
- (2016) A Blackman et al. INTERNATIONAL JOURNAL OF OBESITY
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers
- (2016) Ken Fujioka et al. Obesity
- Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
- (2015) Lisbeth V. Jacobsen et al. CLINICAL PHARMACOKINETICS
- Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points
- (2015) Daisuke Yabe et al. CURRENT MEDICAL RESEARCH AND OPINION
- Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
- (2015) Sten Madsbad DIABETES OBESITY & METABOLISM
- Liraglutide: A Review of Its Use in the Management of Obesity
- (2015) Lesley J. Scott DRUGS
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- European Guidelines for Obesity Management in Adults
- (2015) Volkan Yumuk et al. Obesity Facts
- Incretin Therapy and Pancreatic Pathologies: Background Pathology Versus Drug-Induced Pathology in Rats
- (2014) J. M. Egan et al. DIABETES
- Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials
- (2014) Matteo Monami et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Liraglutide in the treatment of obesity
- (2014) Sarah Yoon Ai Ng et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Potential side effects to GLP-1 agonists: understanding their safety and tolerability
- (2014) Agostino Consoli et al. Expert Opinion On Drug Safety
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
- (2014) Anna Secher et al. JOURNAL OF CLINICAL INVESTIGATION
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
- (2014) Assumpta Caixas et al. Drug Design Development and Therapy
- Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
- (2014) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults
- (2013) M E J Lean et al. INTERNATIONAL JOURNAL OF OBESITY
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
- (2013) Harold E. Bays et al. Obesity
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Liraglutide for type 2 diabetes mellitus
- (2011) Ram Kela et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
- (2010) Anne Flint et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Mild Renal Impairment and the Efficacy and Safety of Liraglutide
- (2010) Jaime Davidson et al. Endocrine Practice
- Effect of Three Different Injection Sites on the Pharmacokinetics of the Once-Daily Human GLP-1 Analogue Liraglutide
- (2010) Christoph Kapitza et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
- (2010) W. Philip T. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide
- (2009) Lisbeth V. Jacobsen et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Pharmacokinetics and Pharmacodynamics of Liraglutide, a Long-Acting, Potent Glucagon-Like Peptide-1 Analog
- (2009) Jerry Meece PHARMACOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More